Active JNJ Drug — Competitive Intelligence Brief

Active JNJ Drug (Active JNJ Drug) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

phase 2 Monoclonal antibody Unknown Oncology Small molecule

Target snapshot

Active JNJ Drug (Active JNJ Drug) — Chengappa, K.N. Roy, MD. Active JNJ drug is a monoclonal antibody that targets a specific molecular target.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active JNJ Drug TARGET	Active JNJ Drug	Chengappa, K.N. Roy, MD	phase 2	Monoclonal antibody	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Continue NA treatment	Continue NA treatment	University Health Network, Toronto	marketed	Unknown	Unknown
oseltamivir and chinese medicinal herbs	oseltamivir and chinese medicinal herbs	Capital Medical University	marketed	Neuraminidase inhibitor combined with herbal supplement	Influenza viral neuraminidase; herbal targets unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Monoclonal antibody class)

1. Pfizer · 7 drugs in this class
2. argenx · 7 drugs in this class
3. Johnson & Johnson · 2 drugs in this class
4. German CLL Study Group · 2 drugs in this class
5. Amgen · 2 drugs in this class
6. Hoffmann-La Roche · 2 drugs in this class
7. Brii Biosciences Limited · 2 drugs in this class
8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
9. Biotest · 2 drugs in this class
10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class